ArticleCancer management and research2026
Hypertriglyceridemia During Anticancer Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia - A Nationwide Experience.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In this study, we aimed to assess the demographics and incidence of hypertriglyceridemia (HTG) during acute lymphoblastic leukemia (ALL) treatment, complications related to HTG, and the treatment strategies applied in pediatric patients treated in pediatric hemato-oncology centers in Poland. Patients and Methods: A total of 72 out of 641 children, aged <18 years with ALL were diagnosed with HTG as a treatment-related complication. Statistical analyses were conducted with a significance level of α = 0.05. Results: The emergence of HTG is a significant complication, with median peak triglyceride levels during treatment reaching 1385.00 mg/dL. Only 5.56% (n = 4) experienced complications. No patients developed pancreatitis. Treatment interruptions were minimal (a median 5.67 days). No children died due to HTG. Management strategies for HTG management included plasmapheresis in 8.3% (n = 6/72). Other therapies - insulin (23.6%, n = 17), heparin (34.7%, n = 25), fibrates (41.7%, n = 30), and omega-3 fatty acids (58.3%, n = 45). A correlation was observed between low antithrombin levels and high TG levels. Conclusion: This is the first nationwide, multicenter analysis conducted across pediatric hemato-oncology centers in Poland evaluating HTG during ALL therapy. HTG occurred in 11.1% of children in the analyzed cohort, and 72% of these cases were grade 3 or 4. With the management strategies applied, severe complications were uncommon and chemotherapy interruptions were generally short. Our findings support the effective triglyceride monitoring; however, triglyceride measurements are currently not standardized and are not performed at predefined time points during treatment. The observed association between low antithrombin levels and high triglyceride concentrations may help identify patients who require closer surveillance. Further prospective studies are needed to define risk factors, optimize prevention and treatment strategies and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.